Difference between revisions of "Imipramine-vortioxetine"

From Psychiatrienet
Jump to: navigation, search
 
(3 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
| to = vortioxetine  
 
| to = vortioxetine  
 
| stop =  
 
| stop =  
* '''Before day 1:''' gradually reduce dosage of imipramine to a maximum of 75 mg/day.
+
{{TCAdecrease25p3d}}
* '''Day 1:''' reduce dosage of imipramine to 50 mg/day.
+
| start = {{StartAntidepressant}}
* '''Day 3:''' reduce dosage of imipramine to 25 mg/day.
+
| info =
* '''Day 8:''' stop administration of imipramine.
+
* Safe target dose vortioxetine = 10 mg
| start =  
 
* A wash-out period is not necessary.
 
* '''Day 8:''' start administration of vortioxetine in a dosage of 10 mg/day.
 
| info =
 
* Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
 
 
}}
 
}}

Latest revision as of 11:33, 30 June 2023

Imipramine
Type Antidepressant
Group TCA
links
Medscape Imipramine
PubChem 3696
PubMed Imipramine
Kompas (Dutch) Imipramine
Wikipedia Imipramine
Vortioxetine
Type Antidepressant
Group SMS
links
Medscape Vortioxetine
PubChem 9966051
PubMed Vortioxetine
Kompas (Dutch) Vortioxetine
Wikipedia Vortioxetine

Switch medication from imipramine to vortioxetine.[1] [2]

Nietinrijdenbord.png Stop imipramine
  • Day 1: Decrease with about 25% of the original dose per 3 days.
Eenrichtingbord.png Start vortioxetine
  • Day 1: Start with 50% of the target dose
  • Day 8: Increase dose to 100% of the target dose
  • Day 9 and after: Gradually increase dose as necessary
Infobord.png More information
  • Safe target dose vortioxetine = 10 mg
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.